<DOC>
	<DOCNO>NCT00174577</DOCNO>
	<brief_summary>The purpose study assess safety efficacy risperidone augmentation patient fail respond partially respond adequate trial antidepressant .</brief_summary>
	<brief_title>Risperidone Augmentation Therapy Patients Who Have Failed Only Partially Responded Trial Antidepressant</brief_title>
	<detailed_description>Specific Aims : The goal study assess safety efficacy risperidone augmentation patient major depression fail respond , partially respond , adequate trial antidepressant medication . Patients meet criterion receive adjunctive risperidone ( 1- 3 mg. ) additional four-week treatment trial . Subject Population : A total sample 84 patient complete study two site ( Rhode Island Hospital/Brown University , n=42 , Emory University , n=42 ) . Methods/Design : Patients meet criterion unipolar depression fail respond , partially respond , adequate trial antidepressant medication randomize risperidone placebo additional 4 week treatment trial continue dose antidepressant medication . Randomization 2:1 ratio risperidone placebo . Data Analysis : Patient outcome ( recovery status ) two treatment condition compare use MADRS rating &lt; 10 denote remission improvement define 50 % decrease baseline end study . Odds ratio examine see risperidone augmentation significantly affect chance recovery depression end 4 week treatment .</detailed_description>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>patient major depression partially remit depression currently receive adequate trial antidepressant diagnosis bipolar I bipolar II disorder psychotic feature substance dependence abuse past three month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>